Comparing Neurofilament Light Chain Levels in Serum and Plasma
Open accessThe claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Some studies report median differences between serum and plasma NfL and GFAP.
“Some studies report median differences,15–18 and only one has proposed a serum–plasma conversion for NfL in older adults, 19 with none for GFAP.”
From Establishing demographic-based normative values for neurofilament light chain and glial fibrillary acidic protein in serum and plasma samples (2026) · cites this paper as [15]
The results section (page not provided) reports different median serum and plasma NfL levels: 27.7 and 29.6 pg/mL, respectively. The paper does not report GFAP measurements or a serum–plasma GFAP comparison, so it supports only the NfL part of the attributed claim. (LLM, conf=0.88)
Experimental — accuracy not yet measuredSystematic differences in absolute values and pre-analytic factors can influence serum and plasma measurements.
“While within-person correlations between serum and plasma are typically strong, systematic differences in absolute values and pre-analytic factors can influence measurements.14–16,19”
From Establishing demographic-based normative values for neurofilament light chain and glial fibrillary acidic protein in serum and plasma samples (2026) · cites this paper as [15]
The main text (page not provided) reports a strong serum–plasma correlation and significantly different absolute NfL levels in the 38 participants. It does not establish that pre-analytic factors influence the measurements; those factors appear only in titles in the References section. (LLM, conf=0.87)
Experimental — accuracy not yet measuredAbsolute values of serum and plasma NfL and GFAP differ, preventing interchangeability.
“While strong intraindividual correlations exist between serum and plasma NfL and GFAP,14–16 absolute values differ, preventing interchangeability.”
From Establishing demographic-based normative values for neurofilament light chain and glial fibrillary acidic protein in serum and plasma samples (2026) · cites this paper as [15]
The study text (page not specified in our copy) reports a strong within-person serum–plasma NfL correlation and significantly different median NfL concentrations. It does not study GFAP or conclude that the difference prevents interchangeability; it says the clinical significance of the NfL difference might be low. (LLM, conf=0.88)
Experimental — accuracy not yet measuredStrong intraindividual correlations exist between serum and plasma NfL and GFAP.
“While strong intraindividual correlations exist between serum and plasma NfL and GFAP,14–16 absolute values differ, preventing interchangeability.”
From Establishing demographic-based normative values for neurofilament light chain and glial fibrillary acidic protein in serum and plasma samples (2026) · cites this paper as [15]
In “Comparing Neurofilament Light Chain Levels in Serum and Plasma,” the authors report a strong within-participant correlation between serum and plasma NfL (Spearman’s rho = 0.961). The paper does not report a serum–plasma GFAP correlation, so it supports only the NfL part of the claim. (LLM, conf=0.90)
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
Forgrave, L. M., Ma, M., Best, J. R., & DeMarco, M. L. (2019) · Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring · doi:10.1016/j.dadm.2019.08.009 · Cited by 177 · see citing works
Seven day pre-analytical stability of serum and plasma neurofilament light chain
Altmann, P., Ponleitner, M., Rommer, P. S., Haslacher, H., Mucher, P., Leutmezer, F., Petzold, A., Wotawa, C., Lanzenberger, R., Berger, T., et al. (2021) · Scientific Reports · doi:10.1038/s41598-021-90639-z · Cited by 68 · see citing works
Flagged first, then by citations
Research works printed but not linked: 6
- [1]Khalil M Teunissen CE Otto M Piehl F Sormani MP Gattringer T Neurofilaments as biomarkers in neurological disorders Nat Rev Neurol 2018 14 577 589 30171200
- [2]Park SA Jang YJ Kim MK Lee SM Moon SY Promising blood biomarkers for clinical use in Alzheimer’s disease: a focused update J Clin Neurol 2022 18 401 409 35796265 PMC9262460
- [4]Mattsson N Andreasson U Zetterberg H Blennow K Alzheimer’s Disease Neuroimaging Initiative Association of plasma neurofilament light with neurodegeneration in patients with Alzheimer disease JAMA Neurol 2017 74 557 566 28346578 PMC5822204
- [5]Lee EH Kwon HS Koh SH Choi SH Jin JH Jeong JH Serum neurofilament light chain level as a predictor of cognitive stage transition Alzheimers Res Ther 2022 14 6 34996525 PMC8742445
- [7]Hviid CV Knudsen CS Parkner T Reference interval and preanalytical properties of serum neurofilament light chain in Scandinavian adults Scand J Clin Lab Invest 2020 80 291 295 32077769
- [8]Syed YY Deeks E [(18)F]Florbetaben: a review in β-amyloid PET imaging in cognitive impairment CNS Drugs 2015 29 605 613 26175116
Cited by
Sorted by citations
Borko, T. L., Ritchie, A., Selva, S., Sillau, S., Engebretson, E., Wolf, A. B., Alvarez, E., Gross, R., Gutierrez, E., Corboy, J., et al. (2026) · Multiple Sclerosis Journal – Experimental, Translational and Clinical · doi:10.1177/20552173261466440 · Cited by 1 · see citing works
- Authors
- Kwon, H. S., Lee, H., Kim, Y. S., Choi, H., Lee, K.-Y., Lee, Y. J., Lee, E.-H., Hwang, M., Park, H., & Koh, S.-H.
- Affiliations
- Hanyang University Guri Hospital (KR)
- Hanyang University (KR)
- Department of Neurology, Hanyang University Guri Hospital, Hanyang University College of Medicine, Seoul, Korea.
- Corresponding author
- Koh, Seong-Ho
- ORCID
- Venue
- Dementia and Neurocognitive Disorders
- Publisher
- XMLink
- Published
- 2023
- Volume
- 22
- Issue
- 3
- Pages
- 109
- ISSN
- 1738-1495 (ISSN-L)
- 2384-0757
- PMC
- PMC10400347
- OpenAlex
- W4385432821
- Cited by
- 15
- References
- 2
- Citations by year
- 2026: 8 · 2025: 4 · 2024: 3
- FWCI
- 2.17
- Type
- journal article
- Language
- en
- Open access
- diamond
- doi.org
- Licence
- Locations
- Dementia and Neurocognitive Disorders (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Skin and Cellular Biology Research
- Health Sciences › Medicine › Physiology › Clinical Laboratory Practices and Quality Control
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Keywords
- neurofilament light chain, serum, plasma, biomarker comparison, cerebrospinal fluid, dementia
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
